Differential expression of insulin receptor substrate-1(IRS-1) in visceral and subcutaneous adipose depots of morbidly obese subjects undergoing bariatric surgery in a tertiary care center in north India; SNP analysis and correlation with metabolic profile
Publication date: Available online 5 May 2021Source: Diabetes &Metabolic Syndrome: Clinical Research &ReviewsAuthor(s): Mukti Sharma, Sandeep Aggarwal, Umakant Nayar, Naval Kishore Vikram, Anoop Misra, Kalpana Luthra
CONCLUSIONS: None of the studies that were assessed met the inclusion criteria of this review. Therefore we were unable to determine the effectiveness of interventions for the management of obesity in individuals with bipolar disorder. Given the extent and impact of the problem and the absence of evidence, this review highlights the need for research in this area. We suggest the need for RCTs that will focus only on populations with bipolar disorder and comorbid obesity. We identified several ongoing studies that may be included in the update of this review. PMID: 32687629 [PubMed - in process]
Lipoprotein insulin resistance (LPIR) is a composite biomarker representative of atherogenic dyslipidemia characteristic of early insulin resistance. It is elevated in obesity and may provide information not captured in hemoglobin A1c (A1C) and homeostatic model assessment for insulin resistance (HOMA-IR). While bariatric surgery reduces diabetes incidence and resolves metabolic syndrome, the effect of bariatric surgery on LPIR is untested.
Lipoprotein insulin resistance (LPIR) is a composite biomarker representative of atherogenic dyslipidemia characteristic of early insulin resistance. It is elevated in obesity and may provide information not captured in glycosylated hemoglobin and homeostatic model assessment for insulin resistance. While bariatric surgery reduces diabetes incidence and resolves metabolic syndrome, the effect of bariatric surgery on LPIR is untested.
The global obesity epidemic over the past decade has led to the development of several surgical therapeutic options for severe obesity, defined as a body mass index (BMI) of 40 kg/m2.1 Patients with BMI of 35 to 39.9 kg/m2 with an obesity-related comorbidity such as diabetes or hypertension and patients with a BMI of>30 kg/m2 and metabolic syndrome, or difficult-to-control diabetes, are also suitable for bariatric surgical procedures.1 Bariatric surgical procedures can be classified into restrictive procedures such as sleeve gastrectomy, malabsorptive procedures such as jejunoileal bypass and biliopancreatic diversion, ...
Conclusions: The LSG is an effective method of treatment in all areas of metabolic syndrome, provides a significant positive clinical outcome in obesity-related comorbidities and induces desirable changes in inflammatory, kidney and liver related biomarkers. PMID: 32117497 [PubMed]
AbstractObesity and insulin resistance are at the centre of most cases of metabolic syndrome (MetS), which may increase the risk of cardiovascular disease approximately 2 ‐fold and type 2 diabetes mellitus approximately 5‐fold. Aside from lifestyle intervention and drug therapy, bariatric surgery (BS) is considered a definitive treatment for this disease.
AbstractOn August 9 –10, 2017, the American College of Surgeons hosted a symposium on metabolic surgery, with 12 follow-on papers published serially in theBulletin of the College. The current synopsis outlines the varied contents of these papers, often in the original words of their authors, who are cited within their topic sections. Topics covered include the following: history and definition of metabolic surgery, bariatric surgery, international bariatric surgery, mechanisms of metabolic surgery, diabetes and the metabolic syndrome, frontiers of metabolic surgery, institutional collaborations, accredita tions...